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By the time a cancer is diagnosed, it comprises billions of 
cells carrying the DNA abnormalities that initiated malignant 
proliferation and many additional genetic lesions acquired 
along the way. Some of these secondary mutations emerge 
owing to selective pressure during tumorigenesis (drivers); 
others may be incidental (passengers), resulting from 
mutational exposures, genome instability or simply the large 
number of cell doublings that leads from a single 
transformed cell to a clinically detectable cancer. To 
distinguish driver from passenger mutations, Greenman et al. 
used a statistical model comparing the observed-to-
expected ratio of synonymous (no amino-acid change) 
mutations with that of non-synonymous (altered amino acid) 
mutations. An increased proportion of non-synonymous 



























    ↓ 
分子標的は情報処理の中枢を潰す 
EGFR-TKI (gefitinib, erlotinib, BIBW2992)                            Lung adenocarcinoma 
Crizotinib                                                                     NSCLC with EML4-ALK fusion 
  
Sirolimus (Rapamycine)                                              LAM (lymphagiomyomatosis) 
 
Imatinib (Gleevec)                                                                 Pulmonary hypertension 



























組織系 （%） 部位 原因 倍増時間 抗がん剤感受性 
扁平上皮がん 30 近位 タバコ 約100日 中等度 
小細胞がん 15 近位 タバコ 約８0日 高感受性 





























     ↓ 
個別化医療の突破口 
東北大学病院呼吸器内科肺癌患者喫煙指数分布 




























喫煙指数 計 男 女
0 137 31 106
1-200 27 16 11
201-400 15 13 2
401-600 57 50 7
601-800 79 67 12
801-1000 103 100 3
1001-1200 75 74 1
1201-1400 27 26 1
1401-1600 32 30 2
1601-1800 21 20 1
1801-2000 12 11 1
2001- 25 24 1




















NEJM, 346: 92-8, 2002. 
Comparison of four chemotherapy regimens for 
advanced non-small-cell lung cancer 
対象：IIIB, IV期 NSCLC 
１．CDDP + TXL         
２．CDDP + GEM 
３．CDDP + TXT 






Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson 
DH; The Eastern Cooperative Oncology Group. 
University of Wisconsin Hospital and Clinics, Madison, USA. 
 
BACKGROUND: We conducted a randomized study to determine whether any of 
three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with 
advanced non-small-cell lung cancer. METHODS: A total of 1207 patients with 
advanced non-small-cell lung cancer were randomly assigned to a reference regimen 
of cisplatin and paclitaxel or to one of three experimental regimens: cisplatin and 
gemcitabine, cisplatin and docetaxel, or carboplatin and paclitaxel.RESULTS: The 
response rate for all 1155 eligible patients was 19 percent, with a median survival of 
7.9 months (95 percent confidence interval, 7.3 to 8.5), a 1-year survival rate of 33 
percent (95 percent confidence interval, 30 to 36 percent), and a 2-year survival 
rate of 11 percent (95 percent confidence interval, 8 to 12 percent). The response 
rate and survival did not differ significantly between patients assigned to receive 
cisplatin and paclitaxel and those assigned to receive any of the three experimental 
regimens. Treatment with cisplatin and gemcitabine was associated with a 
significantly longer time to the progression of disease than was treatment with 
cisplatin and paclitaxel but was more likely to cause grade 3, 4, or 5 renal toxicity (in 
9 percent of patients, vs. 3 percent of those treated with cisplatin plus paclitaxel). 
Patients with a performance status of 2 had a significantly lower rate of survival 
than did those with a performance status of 0 or 1. CONCLUSIONS: None of four 
chemotherapy regimens offered a significant advantage over the others in the 
treatment of advanced non-small-cell lung cancer. 
この時のeditorialのタイトルは「Lung 























しかし、医局員のBasic molecular biologyへの素養が次の展開に繋がった！ 
Nature 2001 Apr 26;410(6832):1111-6  
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. 
Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. 
Adenomatous hyperplasia adenoma 

























EGFR inhibition by ZD1839 
• Chemical class: 
quinazoline
• Orally bioavailable
• Selective inhibitor of 
EGFR tyrosine kinase
– EGFR IC50 = 0.023-0.079 µM
– erbB2 IC50 = 1.2-3.7 µM
• Competitive inhibitor of 
ATP
• Inhibits ligand-induced 
cell growth
































































































（CR:complete response  PR:partial response） 





 250 mg/日 
 500 mg/日 
臨床試験  IDEAL 1における奏功率：驚きと疑問 
Fukuoka M, et al: J Clin Oncol, 21, 2237-46, 2003 
Super-responderの存在が知られるようになった 
 Published at www.nejm.org April 29, 2004  
Activating Mutations in the Epidermal Growth Factor 
Receptor Underlying Responsiveness of Non-Small-Cell 
Lung Cancer to Gefitinib 
Thomas J. Lynch, M.D., …and Daniel A. Haber, M.D., Ph.D.  
Notice: To coincide with the online release of similar findings by Science, this article was published at 
www.nejm.org on April 29, 2004. It will appear in the May 20 issue of the Journal 
Catalytic kinase domain somatic mutation 
Lung adenoicarcinomaで特異な変異やアミノ酸欠落が存在する 






























wild typeとmutant EGFR 
の両方をknock down 
Mutant EGFRでは“oncogene addiction”となって生きている 
↓ 
そのシグナル遮断により肺腺癌はapoptosisに陥る 



















































Kosaka et al. Cancer Res 64, 8919, 2004 
標的薬有効なEGFR変異は女性肺腺がんの50% 
女性肺腺がんの内の有効変異頻度 奏功率 
2/3     x    3/4 =  1/2 タバコを吸わない女性肺がん ５０％が分子標的薬が有効 
EGFR活性型変異頻度 
しかもアジア人に共通 
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Deceased on 06/11/30 
04/07 before 










Clin Cancer Res. 15(13):4493-8. 2009 
例数 奏功率 無増悪生存期間 全生存期間 発表 
東北大学 16 75% 9.7 M MST 未到達 JCO 2006 
埼玉医科大学 27 78% 9.4 M MST 15.4 M BJC 2006 
北海道臨床研究
談話会 





28 78% 9.0 M MST 未到達 
 
JRC 2007 










10μm thick of the 
paraffin-embedded 
samples were sliced and 
transferred to the lab. 
Cells in saline are centrifuged and 
re-suspended in the Buffer AL® 
until use . 
Cells from brushing under 
fibro-optic bronchoscope 
are suspended in the saline 































PNA-LNA PCR clamp method PCR-invader method Direct sequence
G719C ○ ○ △
G719S ○ ○ △





L858R ○ ○ △
L851Q ○ ○ △
exon 21 T790M ○ ○ △
1% 1% 10 -to -20%
Cancer tissue, biopsied samples,
BAL cells, brushing cells,
aspiation samples, paraffin-
embedded samples
Cancer tissue, biopsied samples,





























First line gefitinib versus first line 
chemotherapy by carboplatin (CBDCA) 
plus paclitaxel (TXL) in non-small cell 
lung cancer (NSCLC) patients (pts) 
with EGFR mutations: a phase III study 
(002) by North East Japan Gefitinib 
Study Group. 
 Kobayashi K, Inoue A, Maemondo M, 
Sugawara S, Oizumi S, Saijo Y, 
Gemma A, Morita S, Hagiwara K, 
Nukiwa T; North East Japan Gefitinib 
Study Group, Tokyo, Japan 
North East Japan (NEJ) Gefitinib Study Group 
NSCLC  with 
sensitive EGFR 
mutations 
Stage IIIb/ IV 
No prior chemo. 
PS 0-1 
age of 20-75 y.o 
Gefitinib  












 Institution  
 sex  
 stage 
Maemondo M et al: NEJM, 2010. 
N Engl J Med. 2009 Aug  
Gefitinib or Carboplatin-Paclitaxel in Pulmonary 
Adenocarcinoma. 
Mok TS, Wu YL, Thongprasert S, et al. 
BACKGROUND: Previous, uncontrolled studies have 
suggested that first-line treatment with gefitinib would be 
efficacious in selected patients with non-small-cell lung 
cancer. METHODS: In this phase 3, open-label study, we 
randomly assigned previously untreated patients in East Asia 
who had advanced pulmonary adenocarcinoma and who were 
nonsmokers or former light smokers to receive gefitinib (250 
mg per day) (609 patients) or carboplatin (at a dose calculated 
to produce an area under the curve of 5 or 6 mg per milliliter 
per minute) plus paclitaxel (200 mg per square meter of body-
surface area) (608 patients). The primary end point was 
progression-free survival. RESULTS: The 12-month rates of 
progression-free survival were 24.9% with gefitinib and 6.7% 
with carboplatin-paclitaxel. The study met its primary 
objective of showing the noninferiority of gefitinib and also 
showed its superiority, as compared with carboplatin-
paclitaxel, with respect to progression-free survival in the 
intention-to-treat population (hazard ratio for progression or 
death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; 
P<0.001). In the subgroup of 261 patients who were positive 
for the epidermal growth factor receptor gene (EGFR) 
mutation, progression-free survival was significantly longer 
among those who received gefitinib than among those who 
received carboplatin-paclitaxel (hazard ratio for progression 
or death, 0.48; 95% CI, 0.36 to 0.64; P<0.001), whereas in the 
subgroup of 176 patients who were negative for the mutation, 
progression-free survival was significantly longer among 
those who received carboplatin-paclitaxel (hazard ratio for 
progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; 
P<0.001). The most common adverse events were rash or 
acne (in 66.2% of patients) and diarrhea (46.6%) in the 
gefitinib group and neurotoxic effects (69.9%), neutropenia 
(67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel 
group. CONCLUSIONS: Gefitinib is superior to carboplatin-
paclitaxel as an initial treatment for pulmonary 
adenocarcinoma among nonsmokers or former light smokers 
in East Asia. The presence in the tumor of a mutation of the 












ゲフィチニブ治療前 治療２週後 治療３ヶ月後 
PS不良のEGFR変異例を対象とした救済第Ⅱ相試験 


















Nature. 2007 Aug 2;448(7153):561-6.  
Identification of the transforming EML4-ALK fusion gene in non-small-
cell lung cancer. 
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, 
Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, 

























A: EGFR-TKI + Platinum with  
     Pemetrexed or Docetaxel (n=81) 
 
B: EGFR-TKI + Platinum without 
     Pemetrexed and Docetaxel (n=105) 
Median OS  
  A: 35.8 months 
  B: 23.4 months 







Nat. 471, 110, 2011 









AUC 5  
(N=5) 




CR 0 0 0 
PR 4 8 12  
SD 0 4 4  
PD 1 1 2 

























































J Clin Oncol, 2010 





N Engl J Med. 2005 Feb 24;352(8):786-92.  
EGFR mutation and resistance of non-
small-cell lung cancer to gefitinib. 
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, 
Kocher O, Meyerson M, Johnson BE, Eck MJ, 
Tenen DG, Halmos B. 
T790M is detected in an analysis of the gefitinib 
resistant case 
Structural change in kinase domain causes 
resistant, the same structural mutation resistant 
to Imatinib in cases of CML.  
約半数の耐性機構は？ 
(Haber et al NEJM, 2008) 

J Clin Invest. 2009 Oct;119(10):3000-10. 
Dual targeting of EGFR can overcome a major 
drug resistance mutation in mouse models of 
EGFR mutant lung cancer. 
Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, 
Goel A, Koutcher JA, Spassova M, Ouerfelli O, 









1EGFR G719X, exon 19 deletion, L858R, L861Q; 2Progression of disease (Response Evaluation Criteria in Solid Tumors v1.1) on continuous 
treatment with erlotinib or gefitinib within the last 30 days; 3Amended from original 14-day interval; 4Acquisition of tumor tissue after the 
emergence of acquired resistance was mandated. 
i.v.=intravenous; MTD=maximum tolerated dose; NSCLC=non-small cell lung cancer; SD=stable disease. 










NSCLC with  




SD 6 months 




Partial or complete  
response 
to erlotinib/gefitinib 
MTD cohort expanded up to 80 EGFR 
mutation-positive patients4: 
40 T790M+ and 40 T790M– 
Dose escalation schema 3–6 
patients per cohort 
 
Afatinib p.o. daily + escalating 
doses of i.v. cetuximab q 2 weeks  
 
Dose levels starting at: 
afatinib 40 mg + 
cetuximab 250 mg/m2 
 
Predefined maximum dose: 
afatinib 40 mg + 
cetuximab 500 mg/m2 

Tumor Regression by T790M Mutation Status 
at Recommended Dose 
N Engl J Med. 2008 Jul 24.  
Detection of Mutations in EGFR 
in Circulating Lung-Cancer Cells. 
Maheswaran S, Sequist LV, Nagrath S, Ulkus 
L, Brannigan B, Collura CV, Inserra E, 
Diederichs S, Iafrate AJ, Bell DW, Digumarthy 
S, Muzikansky A, Irimia D, Settleman J, 




       青線：染色体内転座 
b. 次内側緑：ヘテロ接合性消失領域 
c. 次次内側青部：コピー数減少 
        赤部：コピー数増加 
d. 最外側赤点：一塩基変異50000カ所 
●確度の高い一塩基変異 
  50000カ所以上 
●体細胞変異 
  530カ所 
●大規模構造改変 
  43カ所 
全ゲノム情報は予想を凌駕する複雑異常 
Nature. 2010 May 27;465(7297):473-7 
The mutation spectrum revealed by paired 




Cancer Cell. 2010 Jul 13;18(1):63-73. 
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 
unveils a therapeutic strategy for non-small cell lung carcinoma. 















We have investigated the role of individual members of the Raf/Mek/Erk 
cascade in the onset of K-Ras oncogene-driven non-small cell lung carcinoma 
(NSCLC). Ablation of Erk1 or Erk2 in K-Ras oncogene-expressing lung cells 
had no significant effect due to compensatory activities. Yet, elimination of 
both Erk kinases completely blocked tumor development. Similar results were 
obtained with Mek kinases. Ablation of B-Raf had no significant effect on 
tumor development. However, c-Raf expression was absolutely essential for 
the onset of NSCLC. Interestingly, concomitant elimination of c-Raf and B-Raf 
in adult mice had no deleterious consequences for normal homeostasis. 
These results indicate that c-Raf plays a unique role in mediating K-Ras 





Cancer Res 09: Takezawa, Nakagawa 

Chromothripsis 
（chromosome+shattered into pieces） 
Cell, 144, 27, 2011 









































EGFR driver mutation: Gefitinib first (NEJM, 
2010) 
1990 Human genome project by  $3 billion; Dep.  
of Energy and NIH 
 
Collins, F,  (National Human Genome 
Research Institute: NHGRI) 
Venter C, (Celera Genomics, 1988) 
 
  Haemophilus influenzae genome (1995) 
  Saccharomyces cerevisiae genome (1996) 
 
  Caenorhabditis elegans genome (1998) 
 
 
  Drosophila melanogaster genome (2000) 
 
 
  Human genome rough draft (2000) 
 
 
              HapMap project start (2002) 
 
  Human genome project complete       
(2003)    23000 genes 
 
             HapMap project phase I (2005) 
             1000,000 SNPs 
 
Copy number variation (2006) 
$1000/genome project (2006, 
NHRGRI) 
             HapMap project phase II  (2007) 






Human genome project High throughput technology 遺伝子・呼吸器内科 貫和 
MALDI-TOFMS (1994) 
 
Microarray concept (1995) 
 














Affymetrix U133 plus 2.0 (2005) 
 
Pyrosequencing (2005) 
Illumina Solexa genome analizer 
(2005) 
 
Genome-Wide Human SNP Array 6.0 
9 x 105 SNPs with CNV (2007) 
 
DNA nanoarray (2010) 
SMRT (single molecule real time sequencing 
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Human genome project High throughput technology 遺伝子・呼吸器内科 貫和 
MALDI-TOFMS (1994) 
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Affymetrix U133 plus 2.0 (2005) 
 
Pyrosequencing (2005) 
Illumina Solexa genome analizer 
(2005) 
 
Genome-Wide Human SNP Array 6.0 
9 x 105 SNPs with CNV (2007) 
 
DNA nanoarray (2010) 
SMRT (single molecule real time sequencing 
2003, 2010, 2011) 
1995 
1998 
最近20年の猛烈な遺伝子研究技術革新 
21世紀遺伝子研究技術革新（高集積90万SNPs、評価技術、高速演算） 
 2011 
現代基礎研究は臨床に直結している－21世紀医療はゲノム理解が重要！ 
がん（象）の全体像が分かる時代 
